Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy

Cancer types with lower mutational load and a non-permissive tumor microenvironment are intrinsically resistant to immune checkpoint blockade. While the combination of cytostatic drugs and immunostimulatory antibodies constitutes an attractive concept for overcoming this refractoriness, suppression...

Descripción completa

Detalles Bibliográficos
Autores principales: Baumann, Daniel, Hägele, Tanja, Mochayedi, Julian, Drebant, Jennifer, Vent, Caroline, Blobner, Sven, Noll, Julia Han, Nickel, Irena, Schumacher, Corinna, Boos, Sophie Luise, Daniel, Aline Sophie, Wendler, Susann, Volkmar, Michael, Strobel, Oliver, Offringa, Rienk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195409/
https://www.ncbi.nlm.nih.gov/pubmed/32358491
http://dx.doi.org/10.1038/s41467-020-15979-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195409/
https://www.ncbi.nlm.nih.gov/pubmed/32358491
http://dx.doi.org/10.1038/s41467-020-15979-2

Ejemplares similares